Transcriptomics

Dataset Information

0

Tofacitinib modulates cardiometabolic and immunologic disease markers associated with premature atherosclerosis in SLE


ABSTRACT: Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE) and significantly contributes to morbidity and mortality. To date, no pharmacologic intervention has shown to reduce CV risk in SLE. Dysregulation of innate immune responses, including aberrant type I-Interferon (IFN)-neutrophil interactions, has been proposed to significantly contribute to enhanced CV risk in SLE. In lupus animal models, the Janus kinase/signal transducers and activators of transcription (JAK/STAT) inhibitor tofacitinib improves clinical features, immune dysregulation and vascular dysfunction. We hypothesized that JAK/STAT inhibition in SLE subjects would result in amelioration of cardiometabolic and immunologic parameters previously associated with enhanced CVD risk.

ORGANISM(S): Homo sapiens

PROVIDER: GSE139940 | GEO | 2021/03/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-09-11 | E-MEXP-3746 | biostudies-arrayexpress
2018-10-24 | PXD006581 | Pride
2019-02-13 | GSE112755 | GEO
2018-05-09 | GSE110685 | GEO
2019-05-01 | GSE126307 | GEO
2020-12-22 | GSE158924 | GEO
2020-12-22 | GSE158923 | GEO
2011-04-13 | E-GEOD-26950 | biostudies-arrayexpress
2024-08-13 | GSE265793 | GEO
2024-08-13 | GSE214855 | GEO